Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
JAZZ [NASD]
Jazz Pharmaceuticals Public Limited Company
Index- P/E287.00 EPS (ttm)0.66 Insider Own3.30% Shs Outstand60.66M Perf Week1.20%
Market Cap11.49B Forward P/E15.92 EPS next Y11.90 Insider Trans-12.06% Shs Float58.85M Perf Month9.43%
Income58.40M PEG14.59 EPS next Q2.14 Inst Own93.70% Short Float4.31% Perf Quarter7.90%
Sales1.17B P/S9.80 EPS this Y-73.50% Inst Trans-0.18% Short Ratio3.71 Perf Half Y20.54%
Book/sh22.62 P/B8.37 EPS next Y21.83% ROA1.80% Target Price192.29 Perf Year33.79%
Cash/sh11.28 P/C16.80 EPS next 5Y19.67% ROE4.50% 52W Range120.38 - 190.48 Perf YTD15.69%
Dividend- P/FCF31.10 EPS past 5Y43.30% ROI3.70% 52W High-0.56% Beta0.73
Dividend %- Quick Ratio4.50 Sales past 5Y55.60% Gross Margin90.00% 52W Low57.35% ATR4.97
Employees870 Current Ratio4.70 Sales Q/Q39.10% Oper. Margin22.70% RSI (14)62.20 Volatility2.00% 2.79%
OptionableYes Debt/Eq0.98 EPS Q/Q25.60% Profit Margin5.00% Rel Volume0.45 Prev Close189.09
ShortableYes LT Debt/Eq0.97 EarningsMay 05 AMC Payout0.00% Avg Volume684.57K Price189.42
Recom1.80 SMA205.31% SMA507.03% SMA20014.65% Volume307,854 Change0.17%
Feb-25-15Reiterated Deutsche Bank Buy $176 → $185
Feb-20-15Initiated BMO Capital Markets Outperform $200
Nov-05-14Upgrade R. F. Lafferty Neutral → Buy $200
May-09-14Reiterated R. F. Lafferty Neutral $140 → $130
Apr-17-14Initiated Canaccord Genuity Buy $163
Mar-07-14Resumed Barclays Overweight $200
Feb-26-14Reiterated Stifel Buy $145 → $195
Jan-14-14Reiterated UBS Buy $130 → $164
Jan-14-14Downgrade R. F. Lafferty Buy → Neutral $140
Dec-06-13Reiterated UBS Buy $110 → $130
Nov-25-13Reiterated FBR Capital Outperform $105 → $198
Nov-25-13Reiterated Barclays Overweight $112 → $130
Nov-13-13Reiterated R. F. Lafferty Buy $102 → $118
Oct-30-13Initiated FBR Capital Outperform $105
Sep-13-13Reiterated UBS Buy $87 → $98
Aug-22-13Initiated R. F. Lafferty Buy $102
Aug-07-13Reiterated UBS Buy $80 → $87
Aug-07-13Reiterated Cantor Fitzgerald Buy $86 → $97
Aug-07-13Reiterated Barclays Overweight $70 → $85
May-31-13Initiated Stifel Buy $80
Apr-23-15 04:24PM  Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 at noodls
04:05PM  Jazz Pharmaceuticals to Report 2015 First Quarter Financial Results on May 7, 2015 PR Newswire
Apr-18-15 10:41AM  Why This Trader Is Worried About Jazz Pharmaceuticals
Apr-14-15 01:45PM  Hillary Clinton is bashing CEOs -- while taking their money
Apr-13-15 05:17PM  Autohome, Other Foreign Stock Leaders Seen Posting Big Q1 at Investor's Business Daily
Apr-08-15 04:40PM  How Much Further Can Jazz Pharmaceuticals Fall? +6.89%
12:07AM  [$$] New Hedge Fund Strategy: Dispute the Patent, Short the Stock at The Wall Street Journal
Apr-07-15 07:24PM  Kyle Bass's New Tack: Dispute the Patent, Short the Stock at The Wall Street Journal
Apr-01-15 12:01PM  How to make it rain in April
Mar-30-15 08:14AM  Italys Sigma-Tau Rare Diseases Unit Said to Attract Interest at Bloomberg
Mar-23-15 09:11AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Financial Statements
Mar-18-15 08:10AM  Oppenheimer: Bullish Technical Analysis Of 5 Healthcare Names
08:02AM  This Drugmaker Stock Is Attempting A Re-Breakout at Investor's Business Daily
Mar-04-15 04:20PM  Jazz Pharmaceuticals Up on U.S. Approval of Xyrem REMS - Analyst Blog
Mar-03-15 01:04PM  JAZZ PHARMACEUTICALS PLC Financials
06:14AM  Nasdaq 5000 built on biotech this time
Mar-02-15 01:18PM  4 Big-Volume Stocks to Trade for Breakouts: La Jolla Pharma and More at TheStreet
08:16AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Other Events
Feb-26-15 04:54PM  Splunk Shoots Up After Hours; Monster Beverage Also Up at Investor's Business Daily
11:51AM  Jazz Pharmaceuticals Tops Q4 Earnings And Tests Buy Point at Investor's Business Daily
10:10AM  Company News for February 26, 2015 - Corporate Summary
Feb-25-15 03:34PM  Heavy News Day For Several Biotech Stocks
12:28PM  8 Stories JP Morgan Is Watching Today Benzinga
10:23AM  Jazz Pharmaceuticals (JAZZ) Earnings Report: Q4 2014 Conference Call Transcript at TheStreet
09:30AM  Jazz Pharmaceuticals Tops Q4 Earnings, Provides Guidance - Analyst Blog Zacks
Feb-24-15 08:37PM  Jazz Pharmaceuticals Sinks On Outlook, Halt In Drug Trial Benzinga
07:09PM  Jazz tops Street 4Q forecasts AP
06:17PM  Jazz Pharma Tops, But Stock Falls On Guidance Investor's Business Daily
04:50PM  Hewlett-Packard, Jazz Pharmaceuticals Fall After-Hours at Investor's Business Daily
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
04:25PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pr EDGAR Online
11:56AM  Stocks Rise A Bit On Yellen Testimony, Home Depot Results at Investor's Business Daily
07:07AM  Q4 2014 Jazz Pharmaceuticals PLC Earnings Release - After Market Close CCBN
Feb-23-15 05:55PM  Avago, Jazz, MercadoLibre Build Bases Before Q4 Reports at Investor's Business Daily
04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences in March PR Newswire
Feb-20-15 02:37PM  Street Talk: ABBV, ARII, DSW, MRVL & JAZZ CNBC
12:52PM  Coverage initiated on Jazz Pharma by BMO Capital Markets Briefing.com
Feb-18-15 06:07AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Feb-14-15 08:02AM  Actavis Leads IBD 50 Stocks With Earnings This Week at Investor's Business Daily
Feb-13-15 05:07PM  S&P 500 Closes At Record High As Oil Stocks Rebound at Investor's Business Daily
Feb-12-15 08:30AM  Jazz Pharmaceuticals to Present Data on Defibrotide, an Investigational Treatment, in Patients with Hepatic Veno-Occlusive Disease (VOD) at BMT Tandem Meetings PR Newswire
Feb-10-15 04:05PM  Jazz Pharmaceuticals to Report 2014 Fourth Quarter and Full Year Financial Results on February 24, 2015 PR Newswire
Feb-04-15 07:30AM  Lightlake Partner De-Risks Drug Platform; Implies Shares Trade at 1/4 Fair Value Company Spotlight
Jan-22-15 06:36PM  Top World Stocks Close In On Buy Points, New Highs at Investor's Business Daily
Jan-13-15 06:02AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
Jan-12-15 08:29AM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi EDGAR Online
Jan-09-15 10:30AM  Analysts Top 3 Biotech Picks for 2015 With Upside and Takeover Potential at 24/7 Wall St.
Jan-05-15 04:05PM  Jazz Pharmaceuticals to Present at J.P. Morgan Healthcare Conference on January 12 PR Newswire
Dec-31-14 06:44PM  BitAuto, Avago Among 2014's Top World Stocks Winners at Investor's Business Daily
Dec-20-14 08:02AM  Top 5 IBD 50 Stalwarts, Newcomers In Turbulent Year at Investor's Business Daily
Dec-17-14 04:48PM  Equity markets surge...so many stories where to begin? Yahoo Finance Contributors
Dec-12-14 04:33PM  Stocks Close Near Session Lows And Down For The Week at Investor's Business Daily
04:19PM  The rout was on, as major averages post worst weekly loss since 2012 Yahoo Finance Contributors
01:28PM  Stocks Down In Afternoon; Caterpillar, Joy Global Hit at Investor's Business Daily
Dec-11-14 04:05PM  Jazz Pharmaceuticals Initiates Rolling NDA Submission For Defibrotide For The Treatment Of Severe Hepatic Veno-Occlusive Disease PR Newswire
Dec-10-14 01:39PM  JAZZ Pharmaceuticals Slips After Dosing Issue on JZP-386 Zacks
Dec-09-14 11:55AM  Stock Market Today: Wall Street Drops; Conn's Down 40% at Investor's Business Daily
08:30AM  Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update Business Wire
Dec-08-14 06:39PM  Top Global Stocks: Jazz, Actavis In IBD's World List at Investor's Business Daily
03:06PM  Stocks Sink In Late Trading: Tesla, McDonald's Dive at Investor's Business Daily
Dec-04-14 04:21PM  Stock Market Today: Indexes Close With Small Losses at Investor's Business Daily
Dec-03-14 08:50AM  Jazz Pharmaceuticals (JAZZ) Starts Late-Stage Study on Xyrem Zacks
Dec-02-14 06:19PM  Top Funds Gobble Up Tech And Medical Stocks at Investor's Business Daily
04:05PM  Jazz Pharmaceuticals To Present New Analysis Of Defibrotide Data In Patients With Hepatic Veno-Occlusive Disease (VOD) At ASH Annual Meeting PR Newswire
04:05PM  Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem® (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy PR Newswire
Nov-30-14 12:01PM  5 Trade Ideas for Monday: Jazz Pharmaceutical, Capital One, Consolidated Edison, Cerner & Johnson Controls Yahoo Finance Blogs
Nov-26-14 03:24PM  Today's Momo Momentum Stock To Watch: Jazz Pharmaceuticals (JAZZ) at TheStreet
01:01PM  Insider Trading Alert - INTU, JAZZ And STNR Traded By Insiders at TheStreet
Nov-25-14 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences PR Newswire
01:29PM  Stocks Turn Mildly Higher; Taser, Qihoo Gain at Investor's Business Daily
Nov-20-14 03:10PM  Riding The Bull Market With These 2 Momentum ETFs Benzinga
Nov-19-14 06:33PM  Four International IBD 50 Stocks Near Buy Points at Investor's Business Daily
Nov-17-14 06:27PM  Five Ethical Drugmakers Keep Leadership Positions at Investor's Business Daily
Nov-14-14 06:15AM  Is Jazz Pharmaceuticals (JAZZ) a Great Growth Stock? Zacks
Nov-13-14 03:30PM  Sucampo-Takeda Sue Dr. Reddy's for Amitiza Patent Violation Zacks
Nov-06-14 04:05PM  Jazz Pharmaceuticals Announces Participation in Two Investor Conferences PR Newswire
12:05PM  3 Stocks Moving The Drugs Industry Upward at TheStreet
Nov-05-14 04:29PM  New balance of power on Capitol Hillbut no change in stock prices Yahoo Finance Blogs
01:20PM  Jazz Pharmaceuticals Q3 Earnings Rise Y/Y, Lifts Guidance Zacks
10:38AM  Stocks Open To Staggered Gains; Time Warner, NXP, Jazz Climb at Investor's Business Daily
08:50AM  Jazz Pharmaceuticals Public (JAZZ) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
Nov-04-14 08:14PM  These 5 Drugmakers' Earnings Excelled This Quarter at Investor's Business Daily
07:02PM  Jazz Q3 Tops On Defitelio But Regeneron Cuts View Investor's Business Daily
05:11PM  Stocks End Mixed; Jazz Pharma Rises After Hours at Investor's Business Daily
04:30PM  Jazz Pharmaceuticals PLC Earnings Call scheduled for 4:30 pm ET today CCBN
04:13PM  JAZZ PHARMACEUTICALS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EDGAR Online
04:05PM  Jazz Pharmaceuticals Announces Third Quarter 2014 Financial Results And Updated Guidance PR Newswire
07:07AM  Q3 2014 Jazz Pharmaceuticals PLC Earnings Release - After Market Close CCBN
Nov-03-14 04:31PM  It was a lackluster trading session for U.S. equities Yahoo Finance Blogs
02:32PM  Video: 4 Top-Rated Stocks Reporting Earnings Tuesday at Investor's Business Daily
Oct-29-14 08:15AM  Analysts Top 4 Specialty Pharmaceutical Stocks to Buy Before Earnings at 24/7 Wall St.
Oct-21-14 04:05PM  Jazz Pharmaceuticals to Report 2014 Third Quarter Financial Results on November 4, 2014 PR Newswire
Oct-17-14 10:15AM  Insider Trading Alert - AYI, MDSO And JAZZ Traded By Insiders at TheStreet
Oct-15-14 05:04PM  Concert Pharmaceuticals Announces Positive CTP-354 Data Zacks
Oct-10-14 05:37PM  Inversion Vitriol Vs. Drug Consolidation Investor's Business Daily
Oct-09-14 12:15PM  Will Jazz Pharmaceuticals Dance Up The Chart? at Investor's Business Daily
Oct-07-14 06:08PM  Actavis, Jazz, Novo Lead Top World Stocks List at Investor's Business Daily
11:16AM  Zoetis Will Benefit from Industry Trends Gurufocus
Oct-04-14 08:02AM  Medical Stocks End Week On High Note, Biotechs Lead at Investor's Business Daily
Oct-03-14 02:39PM  Jazz Pharmaceuticals Uses New Cash To Buy For Growth at Investor's Business Daily
Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Its products comprise Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate that is in phase I clinical trail for use in patients with narcolepsy. In addition, it develops products in the areas of hematology and oncology, such as JZP-416, which has completed phase I clinical trial for the treatment of patients with ALL who are hypersensitive to E. coli-derived asparaginase; and Leukotac, an anti-CD25 monoclonal antibody that is in phase III clinical trials for the treatment of steroid-refractory acute graft vs. host disease. The company is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COZADD BRUCE CChairman & CEOApr 14Sale181.455,000907,250556,967Apr 16 07:40 PM
Cox Russell J.EVP & COOApr 14Sale181.4550090,72564,553Apr 16 08:10 PM
Hooper Suzanne SawochkaEVP & General CounselApr 14Sale181.454,000725,80048,224Apr 16 08:04 PM
ENRIGHT PATRICK GDirectorApr 06Sale169.1410,0001,691,4196,286Apr 08 04:05 PM
Mulligan SeamusDirectorMar 25Sale174.5950,0008,729,5221,157,205Mar 27 06:20 PM
Mulligan SeamusDirectorMar 18Sale185.0050,0009,250,0001,207,205Mar 20 08:22 PM
Hooper Suzanne SawochkaEVP & General CounselMar 10Option Exercise46.831,85186,68254,075Mar 12 08:27 PM
COZADD BRUCE CChairman & CEOMar 10Sale170.355,000851,750561,967Mar 12 08:16 PM
Hooper Suzanne SawochkaEVP & General CounselMar 10Sale170.361,851315,33652,224Mar 12 08:27 PM
Cox Russell J.EVP & COOMar 05Sale175.1050087,55065,053Mar 09 08:38 PM
WILSON KAREN JSVP, Finance & PAOMar 04Option Exercise28.035,159144,61026,205Mar 05 06:51 PM
WILSON KAREN JSVP, Finance & PAOMar 03Sale176.272,598457,94921,046Mar 05 06:51 PM
ENRIGHT PATRICK GDirectorMar 02Sale176.0010,0001,760,0316,482Mar 04 04:05 PM
Tobias Jeffrey KEVP, R&D & CMOFeb 10Option Exercise46.835,000234,15040,063Feb 12 07:38 PM
Hooper Suzanne SawochkaEVP & General CounselFeb 10Option Exercise46.831,85186,68249,426Feb 12 07:26 PM
ENRIGHT PATRICK GDirectorFeb 10Sale166.8510,0001,668,5186,679Feb 12 04:03 PM
COZADD BRUCE CChairman & CEOFeb 10Sale166.905,000834,500549,131Feb 12 07:19 PM
Hooper Suzanne SawochkaEVP & General CounselFeb 10Sale166.901,851308,93247,575Feb 12 07:26 PM
Tobias Jeffrey KEVP, R&D & CMOFeb 10Sale166.825,000834,11835,063Feb 12 07:38 PM
Hooper Suzanne SawochkaEVP and General CounselJan 13Option Exercise46.831,85186,68249,426Jan 15 07:43 PM
COZADD BRUCE CChairman and CEOJan 13Sale161.735,000808,650554,131Jan 15 07:40 PM
Hooper Suzanne SawochkaEVP and General CounselJan 13Sale161.731,851299,36247,575Jan 15 07:43 PM
ENRIGHT PATRICK GDirectorJan 05Sale160.2510,0001,602,4836,875Jan 07 04:02 PM
Mulligan SeamusDirectorDec 26Sale166.193,308549,7611,257,205Dec 29 07:03 AM
Mulligan SeamusDirectorDec 24Sale165.6313,4172,222,2341,260,513Dec 29 07:03 AM
Mulligan SeamusDirectorDec 23Sale162.2233,2755,397,8961,273,930Dec 29 07:03 AM
ENRIGHT PATRICK GDirectorDec 12Sale170.982,343400,6031,650Dec 16 04:04 PM
Hooper Suzanne SawochkaEVP and General CounselDec 09Option Exercise46.831,34763,08049,647Dec 11 06:25 PM
COZADD BRUCE CChairman and CEODec 09Sale178.795,000893,950559,131Dec 11 06:09 PM
Hooper Suzanne SawochkaEVP and General CounselDec 09Sale178.791,852331,11947,795Dec 11 06:25 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 24Sale170.124,598782,23134,940Nov 25 06:51 PM
Tobias Jeffrey KEVP, Research & Dev and CMONov 14Sale173.321,000173,32039,538Nov 18 05:40 PM
Hooper Suzanne SawochkaEVP and General CounselNov 11Option Exercise46.8366731,23650,101Nov 13 06:55 PM
COZADD BRUCE CChairman and CEONov 11Sale173.635,000868,150564,023Nov 13 06:45 PM
Hooper Suzanne SawochkaEVP and General CounselNov 11Sale173.631,852321,56348,249Nov 13 06:55 PM
ENRIGHT PATRICK GDirectorNov 10Sale171.0910,0001,710,8587,268Nov 12 04:04 PM
McGill IainHead of EUSA Int'l & SVPNov 07Option Exercise50.095,666283,78930,490Nov 10 06:25 PM
McGill IainHead of EUSA Int'l & SVPNov 07Sale172.037,0661,215,53023,424Nov 10 06:25 PM
WILSON KAREN JSVP, Finance & PAONov 06Option Exercise50.347,000352,41028,713Nov 10 05:48 PM
WILSON KAREN JSVP, Finance & PAONov 06Sale170.117,5961,292,15721,117Nov 10 05:48 PM
COZADD BRUCE CChairman and CEOOct 14Sale142.775,000713,850569,023Oct 16 07:06 PM
Tobias Jeffrey KEVP, Research & Dev and CMOOct 10Sale154.041,000154,04040,538Oct 14 06:35 PM
ENRIGHT PATRICK GDirectorOct 06Sale160.5610,0001,605,6337,465Oct 08 06:01 AM
Mulligan SeamusDirectorSep 25Sale161.8414,7062,380,0641,307,205Sep 26 06:45 PM
Mulligan SeamusDirectorSep 24Sale163.7035,2945,777,6921,321,911Sep 26 06:45 PM
Tobias Jeffrey KEVP, Research & Dev and CMOSep 12Sale171.221,000171,22041,538Sep 15 07:10 PM
WILSON KAREN JSVP, Finance & PAOSep 11Option Exercise27.463,00082,38024,713Sep 15 06:53 PM
Mulligan SeamusDirectorSep 11Sale175.0050,0008,750,0001,357,205Sep 15 06:56 PM
WILSON KAREN JSVP, Finance & PAOSep 11Sale175.003,000525,00021,713Sep 15 06:53 PM
COZADD BRUCE CChairman and CEOSep 09Sale170.325,000851,600574,023Sep 10 09:07 PM
Hooper Suzanne SawochkaEVP and General CounselSep 08Option Exercise46.8366731,23652,471Sep 10 09:05 PM
WILSON KAREN JSVP, Finance & PAOSep 08Option Exercise27.462,50068,65024,213Sep 10 09:06 PM
Hooper Suzanne SawochkaEVP and General CounselSep 08Sale168.001,852311,13650,619Sep 10 09:05 PM
WILSON KAREN JSVP, Finance & PAOSep 08Sale170.002,500425,00021,713Sep 10 09:06 PM
ENRIGHT PATRICK GDirectorSep 02Sale162.9410,0001,629,3877,661Sep 04 04:47 PM
Hooper Suzanne SawochkaEVP and General CounselAug 15Option Exercise46.8366731,23652,471Aug 19 07:04 PM
Hooper Suzanne SawochkaEVP and General CounselAug 15Sale150.00667100,05051,804Aug 19 07:04 PM
Winningham Rick EDirectorAug 12Sale133.151,087144,73414,150Aug 14 06:08 PM
Sohn Catherine A.DirectorAug 12Sale133.151,731230,4835,529Aug 14 06:07 PM
ENRIGHT PATRICK GDirectorAug 12Sale133.151,087144,7343,993Aug 14 06:03 PM
BERNS PAUL LDirectorAug 12Sale133.151,087144,7343,993Aug 14 06:01 PM
Hooper Suzanne SawochkaEVP and General CounselAug 12Sale133.151,185157,78351,804Aug 13 06:37 PM
COZADD BRUCE CChairman and CEOAug 12Sale133.155,000665,750579,023Aug 13 06:33 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 11Option Exercise52.744,933260,18847,471Aug 13 06:51 PM
Tobias Jeffrey KEVP, Research & Dev and CMOAug 11Sale135.424,933668,02742,538Aug 13 06:51 PM
Hooper Suzanne SawochkaEVP and General CounselJul 08Option Exercise46.831,85386,77659,407Jul 10 08:09 PM
Keegan FintanEVP, Technical OperationsJul 08Option Exercise46.8346921,96333,741Jul 10 08:14 PM
Keegan FintanEVP, Technical OperationsJul 08Sale155.001,991308,60531,750Jul 10 08:14 PM
Hooper Suzanne SawochkaEVP and General CounselJul 08Sale155.001,853287,21557,554Jul 10 08:09 PM
COZADD BRUCE CChairman and CEOJul 08Sale155.005,000775,000597,067Jul 10 08:04 PM
WILSON KAREN JSVP, Finance & PAOJul 07Option Exercise27.462,50068,65026,169Jul 09 08:12 PM
WILSON KAREN JSVP, Finance & PAOJul 07Sale165.002,500412,50023,669Jul 09 08:12 PM
Mulligan SeamusDirectorJun 25Sale148.64476,9861,405,555Jun 26 08:21 PM
Mulligan SeamusDirectorJun 24Sale149.7049,9537,477,7491,405,602Jun 26 08:21 PM
Cox Russell J.EVP & Chief Operating OfficerJun 20Sale155.002,000310,00057,032Jun 24 07:06 PM
Keegan FintanEVP, Technical OperationsJun 17Sale150.003,750562,50033,272Jun 19 04:01 PM
COZADD BRUCE CChairman and CEOJun 10Sale142.345,000711,700602,067Jun 11 04:36 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Option Exercise48.633,000145,89050,103Jun 11 06:30 PM
Tobias Jeffrey KEVP, Research & Dev and CMOJun 09Sale146.243,000438,72047,103Jun 11 06:30 PM
RIEDEL NORBERT GDirectorMay 28Sale142.4964491,7643,356May 29 07:27 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Option Exercise46.8366731,23657,802May 29 07:24 PM
Hooper Suzanne SawochkaEVP and General CounselMay 27Sale140.0066793,38057,135May 29 07:24 PM
COZADD BRUCE CChairman and CEOMay 13Sale128.925,000644,600606,810May 14 06:09 PM
Keegan FintanEVP, Technical OperationsMay 08Sale136.03750102,02337,772May 12 08:13 PM